Dr. Massimo Cristofanilli Discusses ALK Amplification in Inflammatory Breast Cancer

2 Views
administrator
administrator
07/03/23

Massimo Cristofanilli, MD, Chair in Medical Oncology, Director of Translational Science, Cancer Genome Institute, Fox Chase Cancer Center, discusses the investigation of small-molecule anaplastic lymphoma kinase (ALK) inhibitors to treat patients with inflammatory breast cancer (IBC).

For more information on targeted therapies, visit http://www.onclive.com/specialty/cancer-pathways

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next